80 related articles for article (PubMed ID: 25195836)
1. Pregnancy influences the plasma pharmacokinetics but not the cerebrospinal fluid pharmacokinetics of raltegravir: a preclinical investigation.
Mahat MY; Thippeswamy BS; Khan FR; Edunuri R; Nidhyanandan S; Chaudhary S
Eur J Pharm Sci; 2014 Dec; 65():38-44. PubMed ID: 25195836
[TBL] [Abstract][Full Text] [Related]
2. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.
Calcagno A; Cusato J; Simiele M; Motta I; Audagnotto S; Bracchi M; D'Avolio A; Di Perri G; Bonora S
J Antimicrob Chemother; 2014 Jan; 69(1):241-5. PubMed ID: 23975735
[TBL] [Abstract][Full Text] [Related]
3. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.
Johnson DH; Sutherland D; Acosta EP; Erdem H; Richardson D; Haas DW
PLoS One; 2013; 8(12):e82672. PubMed ID: 24349334
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.
Nirogi R; Bhyrapuneni G; Kandikere V; Muddana N; Saralaya R; Komarneni P; Mudigonda K; Mukkanti K
Biopharm Drug Dispos; 2012 Jul; 33(5):265-77. PubMed ID: 22610784
[TBL] [Abstract][Full Text] [Related]
5. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.
Cattaneo D; Gervasoni C; Meraviglia P; Landonio S; Fucile S; Cozzi V; Baldelli S; Pellegrini M; Galli M; Clementi E
J Antimicrob Chemother; 2012 Feb; 67(2):460-4. PubMed ID: 22127581
[TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.
Laufer R; Paz OG; Di Marco A; Bonelli F; Monteagudo E; Summa V; Rowley M
Drug Metab Dispos; 2009 Apr; 37(4):873-83. PubMed ID: 19144773
[TBL] [Abstract][Full Text] [Related]
7. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.
Brainard DM; Wenning LA; Stone JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Oct; 51(10):1376-402. PubMed ID: 21209233
[TBL] [Abstract][Full Text] [Related]
9. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A; Buclin T; Franc C; Colombo S; Cruchon S; Guignard N; Biollaz J; Telenti A; Decosterd LA; Cavassini M
J Antimicrob Chemother; 2011 Jul; 66(7):1573-81. PubMed ID: 21508009
[TBL] [Abstract][Full Text] [Related]
10. Cefuroxime: pharmacokinetics in cochlear perilymph, cerebrospinal fluid, and plasma.
Sun AH; Parnes LS; Freeman DJ
J Otolaryngol; 1995 Apr; 24(2):134-7. PubMed ID: 7602674
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
[TBL] [Abstract][Full Text] [Related]
12. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
[TBL] [Abstract][Full Text] [Related]
13. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
Barau C; Braun J; Vincent C; Haim-Boukobza S; Molina JM; Miailhes P; Fournier I; Aboulker JP; Vittecoq D; Duclos-Vallée JC; Taburet AM; Teicher E;
Clin Infect Dis; 2014 Oct; 59(8):1177-84. PubMed ID: 24992955
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
Hernández-Novoa B; Moreno A; Pérez-Elías MJ; Quereda C; Dronda F; Casado JL; Madrid-Elena N; Aguilar M; Fumero E; Moltó J; Moreno S
J Antimicrob Chemother; 2014 Feb; 69(2):471-5. PubMed ID: 24097843
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and renal handling of enprofylline in pregnant rats.
Muraoka I; Hasegawa T; Nadai M; Kato K; Nabeshima T
Drug Metab Dispos; 1992; 20(5):653-7. PubMed ID: 1358568
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
Jackson A; D'Avolio A; Watson V; Bonora S; Back D; Taylor J; Armenis K; Gazzard B; Moyle G; Boffito M
J Antimicrob Chemother; 2011 Apr; 66(4):885-9. PubMed ID: 21393207
[TBL] [Abstract][Full Text] [Related]
20. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
